Vaccine development remains a challenge as evasion mechanisms of non-vaccine pathogens are highly developed. In recent years, there have been both successes and failures in the development of new vaccines, and the power of iterative approaches has been increasingly recognized. These combine the discovery of novel antigens, adjuvants, and vectors at the preclinical stage with computational analysis of clinical data to accelerate vaccine development.